First and Next Generation Native rFVIII in the Treatment of Hemophilia A. What Has Been Achieved? Can Patients be Switched Safely?

 

 Buy Article Permissions and Reprints

ABSTRACT

The introduction of plasma-derived human factor VIII (FVIII) and later human recombinant FVIII (rFVIII) has potentially allowed patients suffering from hemophilia A to have a quality of life and life expectancy similar to the population at large. One of the major achievements in molecular biology over the past 15 years was the sequencing of the gene coding for FVIII, leading eventually to the ability to isolate the human gene for FVIII and transfect cells to produce human rFVIII. The first rFVIII products, which are native full-length FVIII molecules, have proved to have an excellent efficacy and safety profile in patients with hemophilia A. Initial concerns about a potential increased inhibitor formation have not been confirmed so far but long-term pharmacovigilance of inhibitor formation is still ongoing. To date, no transmission of hepatitis or human immunodeficiency virus (HIV) attributable to rFVIII products has been reported. However, a theoretical risk of transmission of infectious disease does exist as long as nonsynthetic proteins are used during the production process. The next-generation native rFVIII has been developed to minimize the exposure of patients to animal or human plasma-derived proteins. This has been achieved through major changes to the process of production of rFVIII from baby hamster kidney cells (BHK). This change has included the introduction of a solvent/detergent step and, of more importance, the introduction of a purification procedure without using albumin as a stabilizer. Finally, the rFVIII (BHK) is formulated using sucrose as the final stabilizer to produce the sucrose formulated rFVIII referred to as rFVIII-FS. This article summarizes the recently published pharmacokinetic, safety, and efficacy data for the native rFVIII-FS and compares its clinical profile with that of the first-generation rFVIII.

REFERENCES

• 1 Levine P H. Efficacy of self-therapy in hemophilia: a study of 72 patients with hemophilia A and B.  N Engl J Med . 1974;  291 1381-1384
  PubMedGoogle Scholar
• 2 Aledort L M. Lessons from hemophilia.  N Engl J Med . 1982;  306 607-608
  PubMedGoogle Scholar
• 3 Rizza C R, Spooner R JD. Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-1980; report on behalf of the directors of haemophilia centres in the United Kingdom.  BMJ . 1983;  286 929-933
  PubMedGoogle Scholar
• 4 Scharrer I, Neutzling O, Schwaab R, Oldenburg J, Ehrlich H. Experiences with recombinant factor VIII products: Development of inhibitors and immune tolerance therapy.  Ann Hematol . 1998;  76 A1-A6
  CrossrefPubMedGoogle Scholar
• 5 Beauvais P, Billette de Villemeur T. Prion diseases and blood transfusion.  Transfus Clin Biol . 1999;  6 24-28
  CrossrefPubMedGoogle Scholar
• 6 Abshire T C, Brackmann H H, Scharrer I. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy.  Thromb Haemost . 2000;  83 811-816
  PubMedGoogle Scholar
• 7 Aygoren-Pursun E, Scharrrer I. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. The German Kogenate Study Group.  Thromb Haemost . 1997;  78 1352-1356
  PubMedGoogle Scholar
• 8 Seremetis J, Lusher J M, Abildgaard C F. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy.  Haemophilia . 1999;  5 9-16
  CrossrefPubMedGoogle Scholar
• 9 Lusher J M, Arkin S, Abildgaard C F, Schwartz R S. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. The Kogenate Previously Untreated Patient Study Group.  N Engl J Med . 1993;  328 453-459
  CrossrefPubMedGoogle Scholar
• 10 Lusher J, Arkin S, Abildgaard C F, Hurst D. Recombinant FVIII (Kogenate) treatment for previously untreated patients (PUPs) with hemophilia A: update on the safety and efficacy and inhibitor development after seven study years(Abst PD-664).  Thromb Haemost . 1997;  78(Suppl 1) 162-163
  PubMedGoogle Scholar
• 11 Kreuz W, Manco-Johnson M, Gazengel C. Recombinant FVIII formulated with sucrose (rFVIII-FS) is safe and efficacious in pediatric patients with hemophilia A (Abst).  Blood . 2000;  96 226A
  PubMedGoogle Scholar
• 12 Kreuz W, Escuriola-Ettingshausen C, Martinez-Saguer J, Gunger T, Kornhuber B. Epidemiology of inhibitors in haemophilia A.  Vox Sang . 1996;  70 2-8
  PubMedGoogle Scholar
• 13 Ehrenforth S, Kreuz W, Scharrer I, Kornhuber B. Incidence of development of factor VIII and factor IX inhibitors in haemophilics.  Lancet . 1992;  342 594-598
  PubMedGoogle Scholar
• 14 White B, Cotter M, Bryne M, O'Shea E, Smith O P. High responding factor VIII inhibitors in mild haemophilia-is there a link with recent changes in clinical practices?.  Haemophilia . 2000;  6 113-115
  CrossrefPubMedGoogle Scholar
• 15 Sultan Y, and the French Hemophilia Study Group. Prevalence of inhibitors in a population of 3435 hemophilia patients in France.  Thromb Haemost . 1992;  67 600-602
  PubMedGoogle Scholar
• 16 Scharrer I, Bray G L, Neutzling O. Incidence of inhibitors in haemophilia A patients-a review of recent studies of recombinant and plasma-derived factor VIII concentrates.  Haemophilia . 1999;  5 145-154
  CrossrefPubMedGoogle Scholar
• 17 Scharrer I, Brackmann H H, Sultan Y. Efficacy of a sucrose-formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A.  Haemophilia . 2000;  6 614-618
  CrossrefPubMedGoogle Scholar
• 18 Brackmann H H, Gormsen J. Massive factor VIII infusion in hemophiliacs with factor VIII inhibitors, high responder.  Lancet . 1977;  2 933
  PubMedGoogle Scholar
• 19 Kreuz W, Ehrenforth S, Funk M. Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 year follow-up.  Haemophilia . 1995;  1 24-32
  PubMedGoogle Scholar
• 20 Kreuz W, Becker S, Lenz E. Factor VIII inhibitors in patients with hemophilia A: Epidemiology of inhibitor development and induction of immune tolerance for factor VIII.  Semin Thromb Hemost . 1995;  21 382-389
  PubMedGoogle Scholar
• 21 Mauser-Bunschoten P, Nieeuwenhuis K, Rosendaal G, Van der Berg M. Low dose immune tolerance induction in hemophilia A patients with inhibitors.  Blood . 1995;  86 983-988
  PubMedGoogle Scholar
• 22 Batlle J, Lopez M F, Brackmann H H. Induction of immune tolerance with recombinant factor VIII in haemophilia A patients with inhibitors.  Haemophilia . 1999;  5 431-435
  CrossrefPubMedGoogle Scholar
• 23 Unuvar A, Warrier J, Lusher J M. Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors.  Haemophilia . 2000;  6 150-157
  CrossrefPubMedGoogle Scholar
• 24 Morfini M, Messori A, Longo G. Factor VIII pharmacokinetics: intermittent infusions versus continuous infusions.  Blood Coagul Fibrinolysis . 1996;  7 S27-S33
  PubMedGoogle Scholar
• 25 Hathaway W E, Christian M J, Clark S L, Hasiba U. Comparison of continuous infusion of factor VIII concentrate therapy in hemophilia A.  Am J Hematol . 1984;  17 85-88
  PubMedGoogle Scholar
• 26 Bona R D, Weistein R A, Weisman S J, Barrolomea A, Rickles F R. The use of continuous infusion of factor concentrates in the treatment of hemophilia.  Am J Hematol . 1989;  32 8-13
  PubMedGoogle Scholar
• 27 Hurst D, Zabor S, Malianni D, Millar D. Evaluation of recombinant factor VIII (Kogenate®) stability for continuous infusion using a minipump infusion device.  Haemophilia . 1998;  4 785-789
  CrossrefPubMedGoogle Scholar
• 28 Donna M M, Woloschuk P T, Heather A E. In vitro stability of recombinant factor VIII formulated with sucrose (Abst).  Blood . 1999;  94 3709
  PubMedGoogle Scholar
• 29 Donna M M, Woloschuk P T, Heather A E. In vitro stability of recombinant factor VIII (Kogenate-SF) stored in an ambulatory micro-infuser device (Abst).  Blood . 2000;  96 4021
  PubMedGoogle Scholar
• 30 Lusher J M, Petrini P, Angiolillo A. Antibody and inhibitor patterns in previously untreated patients (PUPs) treated exclusively with B-domain deleted recombinant factor VIII (BDDrFVIII) (Abst).  Blood . 2000;  96 1144
  PubMedGoogle Scholar